Commercializing BiomarkersTherapeutic and Diagnostic Market

A biomarker is, according to the US National Institutes of Health, ?a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.?

Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.

Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.

We can discriminate four main types of molecular biomarkers:

? Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.

? Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.

? Proteomic biomarkers: Base on the analysis of the protein profiles.

? Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).

Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In Commercializing BiomarkersTherapeutic and Diagnostic Market mainly covers consumables, services, software of this market.

Commercializing BiomarkersTherapeutic and Diagnostic Market aims to provide a comprehensive presentation of the global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Commercializing Biomarkers in Therapeutic and Diagnostic Applications. Commercializing BiomarkersTherapeutic and Diagnostic Market contains market size and forecasts of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in global, including the following market information:

• Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Revenue, 2018-2023, 2024-2029, ($ millions)

The global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market was valued at US$ 22010 million in 2022 and is projected to reach US$ 30140 million by 2029, at a CAGR of 4.6% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.

We surveyed the Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market, by Type, 2018-2023, 2024-2029 ($ millions)

Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Segment Percentages, by Type, 2022 (%)

• Consumables
• Services
• Software

• Oncology
• Cardiology
• Neurology
• Other

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

• Key companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications revenues in global market, 2018-2023 (estimated), ($ millions)
• Key companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications revenues share in global market, 2022 (%)
• Further, the report presents profiles of competitors in the market, key players include:
• Roche
• Dako (Agilent Technologies)
• Merck
• BD
• Abbott
• Genesys Biolabs (20/20GeneSystems)
• Affymetrix
• Agendia
• ALMAC
• Arrayit
• Biocartic
• BG Medicine
• KEGG EXPRESSION Database
• Thermo Fisher
• BGI
• Outline of Major Chapters:
• Chapter 1: Introduces the definition of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, market overview.
• Chapter 2: Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size in revenue.
• Chapter 3: Detailed analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
• Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
• Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
• Chapter 6: Sales of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
• Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
• Chapter 8: The main points and conclusions of the report.